Check out this graphic recap of our latest volume and outcomes data in heart transplant, LVAD use, arrhythmia ablation, lead extractions and more.
At Cleveland Clinic Florida, the innovative combination of a temporary left ventricular assist device and bariatric sleeve gastrectomy enabled a patient with Class 3 obesity and advanced heart failure to lose enough weight to receive a heart transplant.
LVAD an underutilized advanced heart failure treatment.
If the findings of a new retrospective study are confirmed in a randomized controlled trial, phosphodiesterase-5 inhibitors could become standard of care in this setting.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
An analysis of the INTERMACS registry finds that use of phosphodiesterase 5 inhibitors after LVAD placement improves survival and reduces thrombotic events, setting the stage for a randomized trial.
A new JACC statement makes the case for earlier referral of patients with advanced heart failure. Our experts review the recommendations and the rationale behind them.
LVAD recipients were much less likely to need an opioid prescription at discharge and much more likely to be free of chronic opioids 18 months later after Cleveland Clinic launched an opioid-sparing regimen.
New protocol is striking because it shows that an opioid-sparing approach can work for patients who’ve undergone a major open-heart procedure.
A new study of over 400 patients with left ventricular assist devices adds to the mixed evidence on atrial arrhythmias in this population and provides the first systematic look at the effects of rhythm control.
Our experts share eight trends and developments that excite them most in mechanical circulatory support and beyond.